18 results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
and Executive Vice President from March 2018 through September 2018. During his nearly 20-year tenure, he was responsible for the clinical development … January 2009 to June 2014. During his tenure at Pfizer Inc., Dr. Rolph also oversaw the Company’s FGF21 program. Dr. Rolph holds a B.Sc
8-K
EX-3.1
ykz05k cxeym
12 Mar 21
Amendments to Articles of Incorporation or Bylaws
5:25pm
DEF 14A
btw gt5ry
27 Apr 20
Definitive proxy
7:30am
8-K
EX-3.2
28dq9mx 50
24 Jun 19
Amendments to Articles of Incorporation or Bylaws
4:17pm
424B4
6kmokh8
20 Jun 19
Prospectus supplement with pricing info
5:20pm
S-1/A
EX-10.8
8cj6ey4g4tln 0iej
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-10.10
4jxz456i
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-3.4
blahpzn c4s8tw2ksdn7
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-10.9
f942ty nvc
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
ju406a av3b5
10 Jun 19
IPO registration (amended)
11:16am
S-1
gd53zmrg67k38
24 May 19
IPO registration
4:18pm
DRS/A
oso1kfxze62woqwngl9
30 Apr 19
Draft registration statement (amended)
12:00am
DRS/A
99jj8o9uyd
19 Mar 19
Draft registration statement (amended)
12:00am
DRS
5zhwu7
17 Jan 19
Draft registration statement
12:00am
- Prev
- 1
- Next